Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AEHAW NYSE:AMPE NASDAQ:CALA NASDAQ:JNP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAEHAWAesther Healthcare Acquisition$0.00$0.01$0.06▼$0.33N/AN/A34,287 shsN/AAMPEAmpio Pharmaceuticals$0.01$0.02$0.00▼$0.13$11K4.76734 shs46 shsCALACalithera Biosciences$0.00$0.00$0.00▼$0.05N/A-2.8212,005 shs194 shsJNPJuniper Pharmaceuticals$11.50$0.00$4.30▼$13.25N/AN/A155,873 shs28,513 shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAEHAWAesther Healthcare Acquisition0.00%0.00%-74.00%-86.32%-94.09%AMPEAmpio Pharmaceuticals0.00%+9,900.00%+270.37%+376.19%-88.89%CALACalithera Biosciences0.00%0.00%0.00%-98.00%-99.20%JNPJuniper Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAEHAWAesther Healthcare Acquisition 0.00N/AN/AN/AAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACALACalithera Biosciences 0.00N/AN/AN/AJNPJuniper Pharmaceuticals 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAEHAWAesther Healthcare AcquisitionN/AN/A0.00∞N/AN/AN/AN/AN/AAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/A∞N/AN/AN/AN/AN/ACALACalithera Biosciences-$39.65MN/A0.00∞N/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAEHAWAesther Healthcare AcquisitionN/AN/AN/AN/AN/AAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACALACalithera BiosciencesN/AN/AN/AN/AN/AJNPJuniper PharmaceuticalsN/AN/AN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals5.73%CALACalithera BiosciencesN/AJNPJuniper Pharmaceuticals45.56%Insider OwnershipCompanyInsider OwnershipAEHAWAesther Healthcare AcquisitionN/AAMPEAmpio Pharmaceuticals3.30%CALACalithera Biosciences6.60%JNPJuniper Pharmaceuticals7.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAEHAWAesther Healthcare Acquisition2N/AN/ANot OptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCALACalithera Biosciences604.87 million4.55 millionNot OptionableJNPJuniper PharmaceuticalsN/AN/AN/AOptionableJNP, AEHAW, AMPE, and CALA HeadlinesRecent News About These CompaniesJuniper Networks invests in AI startup Recogni in $102 million funding roundNovember 13, 2024 | reuters.comAnalysts’ Opinions Are Mixed on These Technology Stocks: Viavi Solutions (VIAV), Silicon Laboratories (SLAB) and Juniper Networks (JNPR)November 1, 2024 | markets.businessinsider.comJuniper beats quarterly estimates on networking gear demandOctober 31, 2024 | reuters.comRNAi biotech Atalanta debuts with $110m plus Biogen and Roche CNS tie-upsAugust 13, 2024 | pharmaphorum.comPCommission approves acquisition of Juniper by HPEAugust 2, 2024 | poandpo.comPJuniper Networks revenue misses estimates on weak client spendingJanuary 30, 2024 | msn.comWhy Juniper Networks Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving PremarketJanuary 9, 2024 | msn.comJuniper Networks Stock (NYSE:JNPR), Analyst Ratings, Price Targets, PredictionsNovember 24, 2023 | benzinga.comJuniper targets data-center management with Apstra upgradeSeptember 24, 2023 | networkworld.comNJuniper Networks’ Julius Francis on Challenges with Local NetworksJune 7, 2023 | eweek.comE‘Juniper’ Review: Charlotte Rampling Burns A Hole In The ScreenMarch 2, 2023 | observer.comOJuniper Essential Oil Market : Reliable Business Data Analysis and Forecast by 2028 with Top Countries DataOctober 20, 2022 | marketwatch.comJuniper, review: Charlotte Rampling outclasses this blindingly predictable odd-couple dramaSeptember 24, 2022 | telegraph.co.ukHelsinn Healthcare SA signs exclusive license agreement with Juniper Biologics Pte. Ltd. for ...September 2, 2022 | kentuckytoday.comKZafgen (ZFGN) Presents Favorable New Data on BeloranibOctober 26, 2021 | finance.yahoo.comNew MarketBeat Followers Over TimeJNP, AEHAW, AMPE, and CALA Company DescriptionsAesther Healthcare Acquisition NASDAQ:AEHAW$0.0026 0.00 (0.00%) As of 07/18/2025Aesther Healthcare Acquisition Corp. intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in New York, New York.Ampio Pharmaceuticals NYSE:AMPE$0.01 0.00 (0.00%) As of 07/18/2025Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Calithera Biosciences NASDAQ:CALA$0.0001 0.00 (0.00%) As of 07/18/2025 09:30 AM EasternCalithera Biosciences, Inc. operates under a plan of liquidation that was approved in January 2023. Previously, the company was engaged in the clinical stage precision oncology biopharmaceutical business. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.Juniper Pharmaceuticals NASDAQ:JNPJuniper Pharmaceuticals, Inc., a diversified healthcare company, focuses on developing novel intra-vaginal therapeutics that address unmet medical needs in women's health. It operates in two segments, Product and Service. The company develops its products utilizing its proprietary drug delivery technologies, which include bioadhesive delivery system, a polymer designed to adhere to epithelial surfaces or mucosa to achieve sustained and controlled delivery of active drug product; and a novel intravaginal ring technology. Juniper Pharmaceuticals, Inc. markets Crinone, a progesterone bioadhesive vaginal gel for progesterone supplementation or replacement as part of an assisted reproductive technology treatment for infertile women with progesterone deficiency. Its product candidates include JNP-0101, which is designed to deliver oxybutynin for the treatment of overactive bladder in women; JNP-0201, which contains natural progesterone and estradiol to be used for hormone replacement therapy in menopausal women; and JNP-0301, a natural progesterone for the prevention of preterm birth in women with a short cervical length. The company offers pharmaceutical product development; clinical trial manufacturing; and analytical and consulting services. Juniper Pharmaceuticals, Inc. has collaboration agreements with Merck KGaA and Allergan, as well as patent license agreement with Massachusetts General Hospital. The company was formerly known as Columbia Laboratories, Inc. and changed its name to Juniper Pharmaceuticals, Inc. in April 2015. Juniper Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/14 - 07/18 Netflix Q2 2025 Earnings: What Investors Need to Know High-Flying GE Aerospace Drops After Blowout Q2 — What Now? A New $70 Billion AI Investment Could Push Taiwan Semiconductor Why Prologis May Be the Smartest Backdoor Bet on AI Real Estate Snap-On: Snap Up This Strong Signal While It’s Still Cheap Why Abbott Laboratories Is a Q2 2025 Buy: Growth & Yield Why Pure Storage Is a Core Investment for the AI Era Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
